Tectonic Therapeutic (TECX) CEO Alise Reicin Receives Award

What Happened Alise Reicin, CEO of Tectonic Therapeutic (TECX), was granted 69,250 derivative shares on September 3, 2026. The Form 4 reports an acquisition price of $0.00 (total reported value $0.00), indicating a compensatory equity award or option rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-09-03; reported on Form 4 filed 2026-09-08 (filed late — 5 days after the transaction).
• Amount: 69,250 shares; reported price per share: $0.00 (derivative award).
• Vesting (per footnote): 1/8 of the shares vest on September 3, 2026; the remaining shares vest in 42 equal monthly installments beginning October 3, 2026, subject to continued service.
• Shares owned after the transaction: not disclosed in this Form 4.
• No immediate sale or cashless exercise was reported — this is a grant/option-style award, not a disposition.

Context This filing documents a compensatory equity award to the CEO, which is common for executive pay and aligns future compensation with company performance. Because it’s a derivative award with a vesting schedule, it does not represent an immediate market purchase or sale; its eventual value will depend on future stock price and continued service. The late filing reduces near-term transparency but does not change the nature of the award.